Insider Buying: National Research Co. (NASDAQ:NRC) Major Shareholder Acquires $33,975.00 in Stock

National Research Co. (NASDAQ:NRC) major shareholder Patrick E. Beans purchased 2,500 shares of the firm’s stock in a transaction on Monday, May 12th. The stock was bought at an average price of $13.59 per share, with a total value of $33,975.00. Following the acquisition, the insider now owns 35,003 shares in the company, valued at $475,690.77. This trade represents a 7.69% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

National Research Price Performance

Shares of NRC stock opened at $13.98 on Friday. The firm has a fifty day simple moving average of $12.68 and a 200-day simple moving average of $15.96. The company has a market capitalization of $320.79 million, a PE ratio of 13.31 and a beta of 0.34. National Research Co. has a twelve month low of $9.76 and a twelve month high of $32.48. The company has a current ratio of 0.47, a quick ratio of 0.47 and a debt-to-equity ratio of 1.30.

National Research (NASDAQ:NRC) last posted its quarterly earnings data on Monday, April 28th. The company reported $0.25 earnings per share for the quarter. National Research had a net margin of 17.32% and a return on equity of 66.52%. The company had revenue of $33.55 million during the quarter.

National Research Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 11th. Stockholders of record on Friday, June 27th will be paid a $0.12 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 3.43%. National Research’s dividend payout ratio (DPR) is presently 46.60%.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Barclays PLC boosted its stake in National Research by 65.6% in the third quarter. Barclays PLC now owns 51,331 shares of the company’s stock valued at $1,175,000 after acquiring an additional 20,331 shares during the period. JPMorgan Chase & Co. increased its position in shares of National Research by 8.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 17,194 shares of the company’s stock valued at $393,000 after purchasing an additional 1,373 shares during the period. QV Investors Inc. raised its position in National Research by 4.5% in the fourth quarter. QV Investors Inc. now owns 354,360 shares of the company’s stock worth $6,251,000 after acquiring an additional 15,370 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of National Research by 35.0% in the 4th quarter. SG Americas Securities LLC now owns 7,298 shares of the company’s stock worth $129,000 after purchasing an additional 1,893 shares in the last quarter. Finally, Inspire Investing LLC lifted its position in shares of National Research by 26.1% during the 4th quarter. Inspire Investing LLC now owns 22,952 shares of the company’s stock valued at $405,000 after acquiring an additional 4,746 shares during the last quarter. Institutional investors own 47.26% of the company’s stock.

About National Research

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.